Allegheny Financial Group’s Vertex Pharmaceuticals VRTX Stock Holding History

Allegheny Financial Group’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.03M	Buy	2,072 +54	+3%	+$23.9K	0.11%	107
2026 Q1	$901K	Buy	2,018 +15	+0.7%	+$6.99K	0.12%	110
2025 Q4	$908K	Sell	2,003 -6	-0.3%	-$2.59K	0.13%	108
2025 Q3	$787K	Buy	2,009 +9	+0.5%	+$3.76K	0.15%	113
2025 Q2	$890K	Hold	2,000	–	–	0.2%	100
2025 Q1	$970K	Sell	2,000 -19	-0.9%	-$8.85K	0.25%	77
2024 Q4	$813K	Sell	2,019 -21	-1%	-$9.73K	0.21%	90
2024 Q3	$949K	Buy	2,040 +19	+0.9%	+$9.13K	0.23%	80
2024 Q2	$947K	Sell	2,021 -240	-11%	-$104K	0.27%	70
2024 Q1	$945K	Sell	2,261 -66	-3%	-$27.9K	0.29%	66
2023 Q4	$947K	Buy	2,327 +21	+0.9%	+$7.76K	0.3%	62
2023 Q3	$802K	Buy	2,306 +306	+15%	+$107K	0.3%	62
2023 Q2	$704K	Hold	2,000	–	–	0.33%	56
2023 Q1	$630K	Hold	2,000	–	–	0.25%	78
2022 Q4	$578K	Hold	2,000	–	–	0.24%	85
2022 Q3	$579K	Hold	2,000	–	–	0.27%	72
2022 Q2	$564K	Hold	2,000	–	–	0.26%	75
2022 Q1	$522K	Hold	2,000	–	–	0.22%	78
2021 Q4	$439K	Buy	+2,000	New	+$389K	0.18%	85

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Allegheny Financial Group's VRTX Position: Q2 2026 in Review

Allegheny Financial Group increased its Vertex Pharmaceuticals (VRTX) stake by 2.7% in Q2 2026, buying an estimated $23.9K and bringing the position to 2,072 shares worth $1.03M. The position accounts for 0.11% of the portfolio, ranked #107.

Allegheny Financial Group first reported a position in VRTX in Q4 2021 and has held it in 19 quarters since. 1,762 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Allegheny Financial Group held 2,072 shares of Vertex Pharmaceuticals worth $1.03M as of Q2 2026.
Allegheny Financial Group bought 54 Vertex Pharmaceuticals shares in Q2 2026, an estimated $23.9K.
Vertex Pharmaceuticals made up 0.11% of Allegheny Financial Group's portfolio in Q2 2026, its #107 holding.
Allegheny Financial Group first reported a position in Vertex Pharmaceuticals in Q4 2021 and has held it in 19 quarters since.
1,762 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Allegheny Financial Group's 13F filing for Q2 2026, filed 22 Jul 2026.